scholarly journals Splenic non-Hodgkin's lymphoma without organomegaly: occult presentation with fatal course and post-mortem diagnosis

Rare Tumors ◽  
2010 ◽  
Vol 2 (1) ◽  
pp. 50-51
Author(s):  
Russell P Gollard ◽  
Diana Garcia
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Post Mortem ◽  
Rare Entity ◽  
Large B Cell Lymphoma ◽  
Splenic Lymphoma ◽  
Fatal Course ◽  
Large B Cell

Splenic lymphoma without splenomegaly is uncommon. We report the case of a 68-year-old female who presented with fulminant B symptoms and thrombocytopenia, only to be found to have micronodular large B-cell lymphoma of the spleen post-mortem. Diagnosis of this rare entity remains difficult and overall prognosis is poor.

scholarly journals Intravascular Large B Cell Lymphoma of the Breast: A Rare Entity

2021 ◽  
Vol 15 ◽  
pp. 117822342110507
Author(s):  
Nitya Prabhakaran ◽  
Hassan Sheikh ◽  
Xinmin Zhang ◽  
Silvat Sheikh-Fayyaz
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Review Literature ◽  
Lymphoid Cells ◽  
Prior History ◽  
Rare Entity ◽  
Treatment Protocols ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Intravascular large B-cell lymphoma (IVLBCL) is a rare and high-grade disease of neoplastic lymphoid cells within the vascular lumina of small- to medium-sized vessels. The disease carries a grim prognosis despite robust treatment protocols. We discuss the case of a 58-year-old female who presented with mammographic screening abnormality which led to more investigations and ultimately to this diagnosis. The patient had no prior history of a lymphoma or in situ and invasive carcinoma of the breast. To our knowledge, IVLBCL of the breast is a very rare and an unusual location for this type of a lymphoma and so far, only five reported cases. Through our case report, we not only discuss the case but also review literature on this rare entity.

Post-transplant lymphoproliferative disorder with Hodgkin's lymphoma and large B-cell lymphoma differentiation

2005 ◽  
Vol 47 (3) ◽  
pp. 333-334 ◽  
Author(s):  
L Novoa-Takara ◽  
A Dincer ◽  
B Kampalath ◽  
P Van Tuinen ◽  
S Hariharan ◽  
...  
Keyword(s):  
B Cell ◽  
Lymphoproliferative Disorder ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Post Transplant ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

2010 ◽  
Vol 28 (12) ◽  
pp. 2085-2093 ◽  
Author(s):  
Anjali Advani ◽  
Bertrand Coiffier ◽  
Myron S. Czuczman ◽  
Martin Dreyling ◽  
James Foran ◽  
...  
Keyword(s):  
Phase I ◽  
B Cell ◽  
Phase I Study ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Inotuzumab Ozogamicin ◽  
Large B Cell Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Large B Cell

Purpose Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. This was a phase I study to determine the maximum-tolerated dose (MTD), safety, and preliminary efficacy of inotuzumab ozogamicin in an expanded MTD cohort of patients with relapsed or refractory CD22+ B-cell non-Hodgkin's lymphoma (NHL). Patients and Methods Inotuzumab ozogamicin was administered intravenously as a single agent once every 3 or 4 weeks at doses ranging from 0.4 to 2.4 mg/m2. Outcomes included MTD, safety, pharmacokinetics, response, progression-free survival (PFS), and overall survival. Results Seventy-nine patients were enrolled. The MTD was determined to be 1.8 mg/m2. Common adverse events at the MTD were thrombocytopenia (90%), asthenia (67%), and nausea and neutropenia (51% each). The objective response rate at the end of treatment was 39% for the 79 enrolled patients, 68% for all patients with follicular NHL treated at the MTD, and 15% for all patients with diffuse large B-cell lymphoma treated at the MTD. Median PFS was 317 days (approximately 10.4 months) and 49 days for patients with follicular NHL and diffuse large B-cell lymphoma, respectively. Conclusion Inotuzumab ozogamicin has demonstrated efficacy against CD22+ B-cell NHL, with reversible thrombocytopenia as the main toxicity.

Primary diffuse large B cell lymphoma of the base of tongue: A rare entity

2014 ◽  
Vol 35 (3) ◽  
pp. 435-438 ◽  
Author(s):  
Aminder Singh ◽  
Neena Sood ◽  
Harpreet Kaur ◽  
Bhavna Garg ◽  
Manish Munjal
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Rare Entity ◽  
Base Of Tongue ◽  
Large B Cell Lymphoma ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document